Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
09 Oct 2019
Future is now: Leaders in Ocular Gene Therapy Meeting, San Francisco (CA)
10 Oct 2019
Ophthalmology Innovation Summit @ AAO, San Francisco (CA)
12 Oct 2019 - 15 Oct 2019
American Academy of Ophthalmology, San Francisco (CA)
05 Sep 2019 - 08 Sep 2019
EURETINA 2019 Congress, Paris, France
26 Jul 2019 - 30 Jul 2019
2019 Annual Meeting ASRS, Chicago, IL (US)
26 Jun 2019 - 29 Jun 2019
UMDF Mitochondrial Medicine 2019, Washington DC, US
16 Jun 2019 - 19 Jun 2019
14th Meeting of EUNOS, Porto, Portugal
13 Jun 2019 - 16 Jun 2019
2019 SOE Congress, European Society of Ophthalmology, Nice, France
03 Jun 2019 - 06 Jun 2019
BIO International Convention, Philadelphia, PA (US)
23 May 2019
KOL Event to present Phase 3 REVERSE&RESCUE results of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON), New York City
View previous 9 articles
1
…
3
4
5
6
7
8
9
10
11
12
13
…
17
View next 9 articles
Go back to the page of the page